Price T Rowe Associates Inc Biotechnology

Price T Rowe Associates Inc

$883 Billion
Q2 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
ARGX Argenx Se	$35.3B	$2.75 Billion 0.31% of portfolio	4,979,976	Q2 2025 Reduced 7.51%
VRTX Vertex Pharmaceuticals Inc	$99.5B	$1.41 Billion 0.16% of portfolio	3,159,870	Q2 2025 Added 8.32%
INSM Insmed Inc	$16.5B	$1.13 Billion 0.13% of portfolio	11,230,705	Q2 2025 Reduced 13.1%
ALNY Alnylam Pharmaceuticals, Inc.	$52.9B	$1.03 Billion 0.12% of portfolio	3,145,006	Q2 2025 Reduced 10.28%
TECH Bio Techne Corp	$2.07B	$455 Million 0.05% of portfolio	8,847,931	Q2 2025 Reduced 22.22%
NVO Novo Nordisk A S	$112B	$428 Million 0.05% of portfolio	6,203,264	Q2 2025 Added 16.5%
REGN Regeneron Pharmaceuticals, Inc.	$59.7B	$402 Million 0.05% of portfolio	766,444	Q2 2025 Reduced 64.76%
ASND Ascendis Pharma A/S	$10.9B	$324 Million 0.04% of portfolio	1,875,491	Q2 2025 Reduced 16.87%
SRRK Scholar Rock Holding Corp	$1.66B	$310 Million 0.04% of portfolio	8,761,650	Q2 2025 Reduced 1.49%
RNA Avidity Biosciences, Inc.	$2.41B	$307 Million 0.03% of portfolio	10,808,727	Q2 2025 Reduced 4.67%
KYMR Kymera Therapeutics, Inc.	$2.18B	$299 Million 0.03% of portfolio	6,859,202	Q2 2025 Added 2.34%
BGNE Bei Gene, Ltd.	$23.5B	$247 Million 0.03% of portfolio	1,020,127	Q2 2025 Reduced 62.4%
AKRO Akero Therapeutics, Inc.	$2.23B	$241 Million 0.03% of portfolio	4,509,325	Q2 2025 Reduced 6.39%
BPMC Blueprint Medicines Corp	$7.73B	$188 Million 0.02% of portfolio	1,464,968	Q2 2025 Reduced 72.95%
RVMD Revolution Medicines, Inc.	$3.09B	$173 Million 0.02% of portfolio	4,701,962	Q2 2025 Reduced 16.03%
VRNA Verona Pharma PLC	$6.41B	$169 Million 0.02% of portfolio	1,789,513	Q2 2025 Reduced 4.11%
CRNX Crinetics Pharmaceuticals, Inc.	$1.53B	$161 Million 0.02% of portfolio	5,590,504	Q2 2025 Added 9.35%
MDGL Madrigal Pharmaceuticals, Inc.	$6.14B	$154 Million 0.02% of portfolio	508,464	Q2 2025 Reduced 6.3%
NUVL Nuvalent, Inc.	$3.29B	$137 Million 0.02% of portfolio	1,795,373	Q2 2025 Added 23.77%
IONS Ionis Pharmaceuticals Inc	$5.85B	$124 Million 0.01% of portfolio	3,126,073	Q2 2025 Reduced 4.26%
MLTX Moon Lake Immunotherapeutics	$2.04B	$123 Million 0.01% of portfolio	2,613,233	Q2 2025 Reduced 12.13%
MRUS Merus N.V.	$2.93B	$119 Million 0.01% of portfolio	2,262,011	Q2 2025 Added 106.44%
VERA Vera Therapeutics, Inc.	$572M	$106 Million 0.01% of portfolio	4,479,717	Q2 2025 Reduced 5.79%
RARE Ultragenyx Pharmaceutical Inc.	$1.97B	$105 Million 0.01% of portfolio	2,886,268	Q2 2025 Reduced 10.33%
PCVX Vaxcyte, Inc.	$1.78B	$103 Million 0.01% of portfolio	3,170,247	Q2 2025 Reduced 10.5%
REPL Replimune Group, Inc.	$259M	$101 Million 0.01% of portfolio	10,819,209	Q2 2025 Reduced 0.32%
ACLX Arcellx, Inc.	$3.19B	$94.7 Million 0.01% of portfolio	1,438,773	Q2 2025 Reduced 21.79%
DNLI Denali Therapeutics Inc.	$1.77B	$92.1 Million 0.01% of portfolio	6,582,295	Q2 2025 Added 50.72%
RYTM Rhythm Pharmaceuticals, Inc.	$5.51B	$84.8 Million 0.01% of portfolio	1,341,392	Q2 2025 Added 11.87%
SMMT Summit Therapeutics Inc.	$5.17B	$83.1 Million 0.01% of portfolio	3,905,148	Q2 2025 Reduced 40.45%
CLDX Celldex Therapeutics, Inc.	$1.11B	$77.7 Million 0.01% of portfolio	3,817,820	Q2 2025 Added 11.94%
CNTA Centessa Pharmaceuticals PLC	$1.61B	$77.6 Million 0.01% of portfolio	5,907,992	Q2 2025 Added 10.59%
AGIO Agios Pharmaceuticals, Inc.	$1.94B	$75.6 Million 0.01% of portfolio	2,274,249	Q2 2025 Reduced 1.18%
MIRM Mirum Pharmaceuticals, Inc.	$2.38B	$72.1 Million 0.01% of portfolio	1,417,215	Q2 2025 Added 0.15%
AXSM Axsome Therapeutics, Inc.	$4.51B	$64 Million 0.01% of portfolio	612,743	Q2 2025 Added 1,816.2%
EXEL Exelixis, Inc.	$12.1B	$64 Million 0.01% of portfolio	1,451,427	Q2 2025 Reduced 10.32%
CYTK Cytokinetics Inc	$3.23B	$61.7 Million 0.01% of portfolio	1,865,977	Q2 2025 Reduced 6.42%
TGTX Tg Therapeutics, Inc.	$3.94B	$55.7 Million 0.01% of portfolio	1,547,544	Q2 2025 Added 296.27%
HALO Halozyme Therapeutics, Inc.	$8.95B	$53.7 Million 0.01% of portfolio	1,032,193	Q2 2025 Reduced 13.02%
PTGX Protagonist Therapeutics, Inc	$2.68B	$51.8 Million 0.01% of portfolio	936,703	Q2 2025 Reduced 29.15%
BEAM Beam Therapeutics Inc.	$1.19B	$41.6 Million 0.0% of portfolio	2,442,876	Q2 2025 Reduced 19.29%
BBIO Bridge Bio Pharma, Inc.	$7.28B	$41.5 Million 0.0% of portfolio	961,216	Q2 2025 Reduced 17.49%
JANX Janux Therapeutics, Inc.	$1.01B	$41.4 Million 0.0% of portfolio	1,793,427	Q2 2025 Added 28.76%
VRDN Viridian Therapeutics, Inc.\De	$717M	$40.5 Million 0.0% of portfolio	2,895,265	Q2 2025 Added 71.51%
IDYA Ideaya Biosciences, Inc.	$1.13B	$40 Million 0.0% of portfolio	1,904,916	Q2 2025 Reduced 45.19%
ADMA Adma Biologics, Inc.	$3.29B	$39 Million 0.0% of portfolio	2,139,240	Q2 2025 Added 1.34%
KRYS Krystal Biotech, Inc.	$3.69B	$35.9 Million 0.0% of portfolio	261,383	Q2 2025 Reduced 36.38%
NRIX Nurix Therapeutics, Inc.	$472M	$34.6 Million 0.0% of portfolio	3,033,844	Q2 2025 Added 4.14%
WVE Wave Life Sciences Ltd.	$734M	$33.7 Million 0.0% of portfolio	5,190,403	Q2 2025 Added 25.82%
UTHR United Therapeutics Corp	$13.7B	$32.9 Million 0.0% of portfolio	114,502	Q2 2025 Reduced 39.65%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.